Company

Bank

Analyst

Coverage

Opinion

Wk chg

3/2 cls

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Leerink

Howard Liang

Price target

Outperform

-3%

$14.68

Liang raised his target to $20 from $14 to reflect an increased probability of clinical and regulatory success for ponatinib. He noted that management reported on its earnings call that it had a "successful" pre-NDA meeting with FDA for the planned submission in 3Q12 based on data from the pivotal Phase II PACE trial of ponatinib to treat chronic resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). In 3Q12, Ariad also plans to submit a regulatory application in Europe and start a Phase III trial of the pan-BCR-ABL tyrosine kinase inhibitor in front-line CML.

Cerus Corp. (NASDAQ:CERS)

Baird

Christopher Raymond

Upgrade

Outperform (from neutral)

0%

$3.57